Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Aug 28, 2026: market cap $1.6B; returns 1 week +0.1%, 1 year +585.6%.

Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and autoimmune-related diseases. Their primary asset is FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate designed to modulate the immune system's T and Natural Killer (NK) cells.

FBRX financial model: income statement, cash flow and balance sheet